Actavis, which is being acquired by Watson Pharmaceuticals (WPI +0.2%), says that on June 29 it...

|By:, SA News Editor

Actavis, which is being acquired by Watson Pharmaceuticals (WPI +0.2%), says that on June 29 it received tentative approval from the FDA for Guanfacine Extended-Release Tablets, a generic equivalent to Shire's (SHPGY -2.5%) Intuniv. Intuniv had US sales of approximately $342M for the 12 months ending March 31.